DIRMC

A Database of Immunotherapy-Related Molecular Characteristics

Analysis Interface

In the analysis interface, you can clearly see the specific target of each type of immunotherapy. The target with a red background indicates that the target has an approved immunotherapy, and the yellow background indicates that the drug for the target is currently in the clinical research stage. If you want to know the current research status of a specific target, which drugs are approved, and what diseases are these drugs designed for, you can learn more by clicking on the specific target.

If you want to predict the binding affinity of both MHC (including, MHC I and MHC II) and peptide, and TCR and peptide, you can choose different methods to predict the relevant results by selecting the option of MHC & peptide or TCR & peptide in the "Predict you want" box below.
Predict you want
ANG2/VEGF
Angiopoietin
BCMA/CD3
CA-125
CCR4
CD19/CD3
CD20/CD3
CD22/CD28
IL-2/IL-2Rα/IL-2Rβ
CD30
CD33
CD37
CD38
CD40
CD52
CD56
CD123
CEA
cMET
CSF1R
DLL/Notch
DLL4/VEGF
DNA topoisomerase 1
EGFR/cMET
EpCAM
FGF/FGF-R
GD2
HER2
Mesothelin
Nectin-4
PDGFRα
RANKL
SLAMF7
Tissue factor
TNF-R1
TROP2
VEGF/VEGF-R
Claudin 18.2
DKK1
Network Analysis Results
Gene
Target
Drug
Disease
Analysis Result Table
CSV
Network Analysis Results
This target has not yet been studied in clinical trials, and there is no clear evidence of target interaction. We will update the information in time if relevant data appears in the follow-up. If you have evidence to support this target relationship, you can also provide it to us on the Submission page, and we greatly appreciate your submission.
CopyRight © Center for Bioinformatics, Harbin Institute of Technology, China.